Tigecycline: A novel broad-spectrum antimicrobial

Annals of Pharmacotherapy

Volumn 41, Issue 6, 2007, Pages 965-972

  Slover, Christine M ^a   Rodvold, Keith A ^a   Danziger, Larry H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Glycylcycline; Tigecycline

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; AZTREONAM; BETA LACTAMASE; CILASTATIN PLUS IMIPENEM; DIGOXIN; GLYCYLCYCLINE DERIVATIVE; METOCLOPRAMIDE; ONDANSETRON; PROCHLORPERAZINE; TIGECYCLINE; TRIMETHOBENZAMIDE; VANCOMYCIN; WARFARIN; DRUG DERIVATIVE; MINOCYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BLEEDING; BLOOD CHEMISTRY; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HUMAN; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; PSEUDOMONAS; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; BACTERIAL INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; MINOCYCLINE;

EID: 34250163180     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H543     Document Type: Review

References (40)

1. Package insert. Tygacil (tigecycline) for injection. Philadelphia, PA: Wyeth Pharmaceuticals, June 2005.
2. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-4.
3. Tygacil clinical monograph. Philadelphia, PA: Wyeth Pharmaceuticals, September 2005.
4. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(suppl 5):S303-14.
5. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-71.
6. Bergeron J, Ammirati M, Danely D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal site and evade Tet(M)-and Ete(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-8.
7. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro activity of tigecycline against 3989 gram-negative and gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST program; 2004). Diagn Microbiol Infect Dis 2005;52:173-9.
8. Bouchillon SK, Hoban DJ, Johnson BM, et al. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005;51:291-5.
9. Sadcv HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritschc TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005;52:181-6.
10. Snydman DR, Jacobus NV, McDermott LA. Evaluation of the in vitro activity of NVP-LMB415 against clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. J Antimicrob Chemother 2005;55:1024-8.
11. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005;49:5024-32.
12. Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000;6:159-63.
13. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000;16:61-3.
14. Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous Mycobacteria. Antimicrob Agents Chemother 2002:46:3164-7.
15. Performance standards for antimicrobial susceptibility testing. CLSI document M100-S16 (M2, M7). Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
16. 2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-9.
17. Hirata T, Satio A, Nishino K, Tamura N, Yamaquchi A. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004;48:2179-84.
18. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(suppl 5):S341-53.
19. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group: Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(suppl 5):S354-67.
20. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii blood-stream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31.
21. Draghi DC, Tench SL, Jones ME, et al. Longitudinal analysis of tigecycline (TIG) activity against geographically diverse Staphylococcus aureus (SA), Acinetobacter spp. (AB), and Enterobacteriaceae (EN) exhibiting multi-drug resistant (MDR) phenotypes (abstract). Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. American Society of Microbiology, E-0744.
22. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9.
23. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005;17(suppl 1):12-22.
24. Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effect of age and sex in single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49:1656-9.
25. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E; Tigecycline 200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004;26:704-14.
26. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32.
27. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue,and body fluid concentrations of tigecycline after a single 100-mg dose. J Antimicrob Chemother 2006;58:1221-9.
28. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-9.
29. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006;58:256-65.
30. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20(9 pt 2):219S-23S.
31. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9
32. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-24.
33. Dukart C, Dartois N, Cooper CA, Gandjini H, Ellis-Groose EJ; Tigecycline 308 Study Group; Tigecycline 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline (TGC) with levofloxacin (LEV) in patients (pts) with community-acquired pneumonia (CAP) (abstract) . Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-30, 2006. American Society of Microbiology, L-1450.
34. U.S. National Institutes of Health. ClinicalTrials.gov. http://clinicaltrials.gov/ct/search;jsessionid=8877FE17DDB (accessed 2006 Oct 31).
35. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006;38:1081-4.
36. Frampton JE, Curran MP. Tigecycline. Drugs 2005;65:2623-35.
37. Raible DG, Zimmerman JJ, Harper DM, Speth JL. Pharmacokinetics and pharmacodynamics of tigecycline and warfarin coadministered to healthy subjects (abstract). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005. American Society of Microbiology, A-21.
38. Zimmerman JJ, Harper DM, Speth JL, et al. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men (abstract). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004. American Society of Microbiology, A-460.
39. Baines SD, Saxton K, Freeman J, Wilcox MH. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006;58:1062-5.
40. Drug topics red book. Montvale, NJ: Thomson Healthcare, 2006. Wanda T Maldonado Chantal Guévremont